Related Experiment Video
Updated: Jun 29, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative
Concetta Calabrò1, Giuseppe De Palma2, Tarik Gheit3
1Pharmacy Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Introduction:
Immune checkpoint inhibitors (ICIs) have reshaped the therapeutic landscape of head and neck squamous cell carcinoma (HNSCC). However, only a subset of patients derives durable benefit, highlighting the need for reliable predictive factors of response.
Areas Covered:
A literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science (2015-2026) using relevant keywords. This narrative review summarizes and categorizes currently available evidence on biological, inflammatory and clinical biomarkers associated with response to immunotherapy in HNSCC, with particular attention to PD-L1 expression, HPV status, tumor mutational burden, immune microenvironment, systemic inflammatory indices and performance status.
Expert Opinion:
PD-L1 expression assessed by Combined Positive Score (CPS) remains the only validated clinical biomarker, although its dynamic and heterogeneous nature limits accuracy. HPV positivity, high tumor mutational burden, favorable immune microenvironment, low neutrophil-to-lymphocyte ratio and good Eastern Cooperative Oncology Group Performance Status (ECOG PS) are consistently associated with improved outcomes. No single marker adequately predicts. Response to immunotherapy in HNSCC is multifactorial. Integrating biological and clinical parameters may support a personalized approach to immunotherapy.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:44Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
Published on: April 3, 2026
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...